Ari Wald, Oppenheimer, joins 'Power Lunch' to discuss Wald's investing take on three stocks: Apple, Rockwell Automation and Gilead Sciences. Read more
Cnbc - Nov 24
Truist Financial reaffirmed their buy rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report issued on Monday morning,Benzinga reports. Truist Financial currently has a $145.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $1... Read more
Defenseworld Net - Nov 04
On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.The ongoing, multi-arm, global P... Read more
Benzinga - Oct 13
Changes in a federal healthcare authority could negatively impact one of the company's important businesses. Read more
Fool - Jul 28
